Licensing

Cellartis is working to bring innovative human ES derived products to the market to improve the drug discovery process by enabling early studies on normal human high-quality cell material. To achieve this, Cellartis is actively seeking partners that wish to participate in the development of novel drug discovery applications based on Cellartis’ novel cell platform.

Cellartis’ proprietary human ES platform consists of cardiomyocytes, hepatocytes, mesenchymal progenitor cells and undifferentiated cells. The company seeks to leverage the platform by working with interested third parties on a license or collaboration basis.

To learn more about these opportunities, please contact:

Katarina Emanuelsson
Business Development Manager
Gothenburg, Sweden
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it.

SELECTED EXAMPLES OF ONGOING PARTNERSHIPS

Novo Nordisk, Denmark and Lund University, Sweden: Project to derive insulin-producing cells from stem cells to treat diabetes

Mitsubishi Tanabe Pharma, Japan: Parkinson's disease.
 

Invitrogen, USA: multi-lineage reporter stem cell lines.

Vitrolife, Sweden: hES cell culture media

TATAA Biocenter, Sweden: specific characterization tools.